Bruker AXS to Acquire X-Ray Analysis Software Company SOCABIMNext generation DIFFRACPlus Eva XRD software provides a unique, ful

Bruker AXS GmbH today announces that it has signed a
binding agreement to acquire all shares of privately-held SOCABIM SAS,
a company focused on advanced X-ray materials research and analysis
software. The transaction is expected to close in the first quarter of
2006.
   SOCABIM was founded in 1977 and has developed into a major
supplier of software for X-ray diffraction (XRD) and X-ray
fluorescence (XRF) materials analysis to Bruker AXS. With this
acquisition, Bruker AXS is significantly expanding its core technology
base in two of its strategic product and applications areas. The
acquisition will not add to Bruker AXS' revenue, but is expected to
increase the Bruker AXS gross margin by more than one percent. For
Bruker BioSciences Corporation the transaction is expected to be
accretive by $0.01 per share in 2006.
   Bruker AXS intends to merge and co-locate SOCABIM SAS and its
French subsidiary Bruker AXS SA near Paris. The two co-founders of
SOCABIM, Mr. Julien Nusinovici and Mr. Pierre Caussin, as well as all
present employees of SOCABIM, are expected to join the merged company,
with Mr. Nusinovici and Mr. Caussin continuing their role as senior
managers of the SOCABIM division of the merged company.
   Dr. Frank Burgazy, Managing Director of Bruker AXS GmbH and
President of Bruker AXS SA in France, said: "We are very excited about
this acquisition and we welcome our new SOCABIM colleagues to Bruker
AXS. The already high quality and good market acceptance of the
SOCABIM software should be further increased by our strategic
integration of the SOCABIM software R&D. We believe that with the
addition of the SOCABIM technology and R&D team, our products can
accelerate their 'time-to-market', and our X-ray systems for advanced
research and process analysis in the nanomaterials, thin film,
composite materials, semiconductor and basic materials industries will
be even more powerful and user-friendly."
   Mr. Julien Nusinovici, President of SOCABIM SAS, added: "My
SOCABIM colleagues and I are very pleased to join Bruker AXS, where we
see an excellent opportunity to continue our successful software
development work in an integrated X-ray analysis solutions
environment. We look forward to contributing significantly to the
success of Bruker AXS in the future."

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science and advanced materials research tools
based on x-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
For more information, please visit www.bruker-biosciences.com.

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, exposure to currency
fluctuations, changes in governmental regulations, capital spending
and government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our respective annual reports on Form
10-K for the year ended December 31, 2004, our most recent quarterly
reports on Form 10-Q, and our current reports on Form 8-K. We disclaim
any intent or obligation to update these forward-looking statements.